Artivion, Inc. (AORT)

NYSE: AORT · IEX Real-Time Price · USD
12.12
+0.09 (0.75%)
Mar 21, 2023, 4:00 PM EDT - Market closed
0.75%
Market Cap 510.27M
Revenue (ttm) 313.79M
Net Income (ttm) -19.19M
Shares Out 42.10M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE 357.14
Dividend n/a
Ex-Dividend Date n/a
Volume 167,063
Open 12.30
Previous Close 12.03
Day's Range 11.96 - 12.49
52-Week Range 9.64 - 23.43
Beta 1.39
Analysts Buy
Price Target 23.03 (+90.02%)
Earnings Date May 4, 2023

About AORT

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 11, 1993
Employees 1,300
Stock Exchange NYSE
Ticker Symbol AORT
Full Company Profile

Financial Performance

In 2022, Artivion's revenue was $313.79 million, an increase of 5.00% compared to the previous year's $298.84 million. Losses were -$19.19 million, 29.4% more than in 2021.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AORT stock is "Buy." The 12-month stock price forecast is $23.03, which is an increase of 90.02% from the latest price.

Price Target
$23.03
(90.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference

ATLANTA , March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the...

2 weeks ago - PRNewsWire

Artivion (AORT) Q4 Earnings Surpass Estimates

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Artivion Reports Fourth Quarter and Full Year 2022 Financial Results

Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of 2021, flat on a GAAP basis and an increase ...

1 month ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results

ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 fin...

1 month ago - PRNewsWire

Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?

Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Wall Street Analysts Think Artivion (AORT) Could Surge 79%: Read This Before Placing a Bet

The consensus price target hints at a 79.4% upside potential for Artivion (AORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

4 months ago - Zacks Investment Research

Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 173.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the posi...

4 months ago - Zacks Investment Research

Artivion to Participate in Upcoming Investor Conferences

ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...

4 months ago - PRNewsWire

Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates

Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Artivion Reports Third Quarter 2022 Financial Results

Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11...

4 months ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results

ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results...

5 months ago - PRNewsWire

Elizabeth Hoff Joins Artivion Board of Directors

ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A.

6 months ago - PRNewsWire

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ --- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery ...

6 months ago - PRNewsWire

Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference

ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deu...

6 months ago - PRNewsWire

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase

ATLANTA , Aug. 24, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upc...

7 months ago - PRNewsWire

Artivion Reports Second Quarter 2022 Financial Results

ATLANTA , Aug. 4, 2022 /PRNewswire/ --  Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, ...

8 months ago - PRNewsWire

What Makes Artivion (AORT) a New Buy Stock

Artivion (AORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission ATLANTA , July 27, 2022 /PRNewswire/...

8 months ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2022 Financial Results

ATLANTA , July 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2022 financial result...

8 months ago - PRNewsWire

Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?

Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

9 months ago - Zacks Investment Research

Artivion to Participate in the UBS 2022 Global Healthcare Conference

ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming U...

11 months ago - PRNewsWire

Artivion Reports First Quarter 2022 Financial Results

Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLAN...

11 months ago - PRNewsWire

ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results

ATLANTA, April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results...

11 months ago - PRNewsWire

Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference

ATLANTA, March 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming ...

1 year ago - PRNewsWire

Artivion Publishes Inaugural Corporate Responsibility Report

ATLANTA, March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Re...

1 year ago - PRNewsWire